Utility of C-terminal Telopeptide in Evaluating Levothyroxine Replacement Therapy-Induced Bone Loss

Alap L. Christy, Vivian D’Souza, Ruby P. Babu, Sohil Takodara, Poornima Manjrekar, Anupama Hegde and M. S. Rukmini
Department of Biochemistry, Kasturba Medical College, Manipal University, Mangalore, India.

ABSTRACT
BACKGROUND: Levothyroxine (LT4) therapy has shown to have effects on bone metabolism though its deleterious effect on bone remodeling is debatable. This study was aimed at assessing the diagnostic utility of the bone remodeling marker C-terminal telopeptide (CTx) in detecting early bone loss.

MATERIALS AND METHODS: In this case–control study, 84 premenopausal women of 30–45 years of age were selected. Out of them, 28 were recently diagnosed of hypothyroidism (not on LT4), 28 were on LT4 replacement therapy (100–200 µg/day) for more than five years, and 28 had euthyroid. Plasma CTx levels were estimated. Bone mineral density (BMD) was measured by quantitative ultrasound (QUS) method. Pearson’s coefficient of correlation and ANOVA were used for statistical analysis.

RESULTS: CTx was most elevated in LT4-treated group (0.497 ± 0.209 ng/mL). It showed a significant negative correlation with T-score and Z-score of BMD values. In the treatment group of more than 150 µg/day, CTx showed significantly negative correlation with TSH (r = −0.462, P = 0.047).

CONCLUSION: LT4 therapy induces bone loss in hypothyroid patients. CTx levels can measure such bone loss along with BMD. Regular monitoring of CTx with adjustment in LT4 doses may help delay osteoporosis induced by prolonged LT4 replacement therapy.

KEYWORDS: hypothyroidism, bone loss, C-terminal telopeptide, LT4 – levothyroxine therapy, Bone mineral density, bone remodeling, osteoporosis.

CITATION: Christy et al. Utility of C-terminal Telopeptide in Evaluating Levothyroxine Replacement Therapy-Induced Bone Loss. Biomarker Insights 2014:9 1–6
doi: 10.4137/BMI.S13965

RECEIVED: December 19, 2013. RESUBMITTED: January 27, 2014. ACCEPTED FOR PUBLICATION: January 28, 2014.

ACADEMIC EDITOR: Karen Pulford, Associate Editor

TYPE: Original Research

FUNDING: Author(s) disclose no funding sources.

COMPETING INTERESTS: Author(s) disclose no potential conflicts of interest.

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

CORRESPONDENCE: drpamanjrekar@gmail.com

Introduction
Hypothyroidism is a state of thyroid hormone deficiency.1 Its overall incidence is 2–15% in the general population.2 Thyroid hormone preparations are widely used to correct hypothyroidism of various etiologies. In many cases of hypothyroidism, slightly supraphysiological doses of thyroxine (levothyroxine (LT4)) are administered resulting in suppression of TSH (thyroid-stimulating hormone). It has been observed that long-term treatment with LT4 is associated with ill effects such as reduced bone mass and increased incidence of fractures.3 A study done by De Rosa et al.4 suggests that suppressive doses of LT4 significantly increase the bone turnover and lead to a reduction in bone mineral density (BMD), more in cortical bone, in both pre- and post-menopausal hypothyroid women. The possible reason behind this is that, in the presence of excess thyroid hormone, bone formation and bone resorption both increase, but bone resorption exceeds bone formation resulting in bone loss.4

There are various indices available to measure such bone loss. BMD measurement by densitometry is the gold standard method.5,6 It is measured by various techniques such as dual energy X-ray absorptiometry (DEXA) and quantitative ultrasound (QUS). Though DEXA is the most reliable method of BMD estimation, QUS has also proven to be an equivalent predictor of fracture risk in patients of osteoporosis. QUS has an advantage that it provides information not only on
bone mass but also on bone elasticity and structure. BMD is expressed as T-score and Z-score. Z-score being a better indicator of bone loss in premenopausal women is preferred over T-score to detect bone loss in this group.

Although BMD measurement is a definitive indicator of bone status, its use has been limited to only diagnosis and not to monitor the bone loss, mainly because of its high cost.

Several biochemical markers are available to measure such bone loss. Markers of bone turnover such as osteocalcin, bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase, urine hydroxyproline and deoxypyridinoline, serum and urine N-terminal and C-terminal telopeptides (CTx) of type I collagen cross-links have been studied extensively for their use in measuring bone loss induced by postmenopausal osteoporosis or other causes.

Among the aforementioned markers, CTx has gained considerable interest in monitoring the response to bisphosphonate therapy in cases of osteoporosis. Osteoclasts produce a number of proteolytic enzymes capable of degrading the organic bone matrix, thus releasing calcium and a large variety of collagen breakdown products into the serum. CTx is one of the collagen breakdown product. Though it has been used to measure bone loss in hyperthyroidism and LT4 suppressive therapy, data of its use in LT4 replacement therapy-induced bone loss are still limited.

This study was aimed at evaluating the attributes of CTx in subjects with LT4 replacement therapy-induced bone loss and to assess its diagnostic utility as a cheaper and more convenient alternative to the conventional investigations.

**Material and Methods**

**Study population.** A case–control study was conducted at KMC Hospital (KMCH), Ambedkar Circle and KMCH, Attavar, Mangalore from November 2011 to October 2012. On the basis of T3, T4, and TSH levels, a total of 84 premenopausal women in age group of 30–45 years were selected and divided into three groups: Group 1 (28 hypothyroid women on LT4 therapy (100–200 µg/day) for minimum five years), Group 2 (28 premenopausal women of newly diagnosed hypothyroidism as first controls to match the hypothyroidism), and Group 3 (28 age-matched euthyroid women as second controls) (Fig. 1). Informed consent was obtained from the subjects. The study was approved by research and ethics committee of the institution.

**Post-thyroidectomy patients on suppressive doses of LT4; patients with bone and joint disorders, and hypertension; patients on anticonvulsant, chemotherapeutic agents, glucocorticoids, and oral contraceptive pills; patients on vitamin D and calcium for last four months or more; patients with long-term immobilization, malignancy, lung diseases; pregnant and lactating women; and patients with hysterectomy were excluded from the study.**

Blood samples were collected in the fasting state in EDTA vacutainer. Samples were immediately centrifuged, and plasma was separated and stored at −20 °C until analysis. Serum CTx was measured using cobas e 411 hormone analyzer by electrochemiluminescence immunoassay (ECLIA) based on the sandwich principle using Elecsys β-CrossLaps kits by Roche diagnostics, Mannheim as per the manufacturer’s instructions. BMD of all the subjects was measured at the orthopedics outpatient department using the QUS method with the portable ultrasound device at the heel.

**Statistical analysis.** Data were analyzed using IBM SPSS Statistics version 20. Data are presented as mean ± SD. Comparison of group means was done using ANOVA, Tukey’s method. Pearson’s correlation was done to evaluate correlation between variables. *P* value <0.05 was considered significant.

**Results**

Baseline characteristics are shown in Table 1. There is no significant difference in age among the three groups. TSH and T3 showed significant difference, with TSH being highest in the newly diagnosed hypothyroid individuals. T4 did not show any significant difference. CTx levels were elevated in premenopausal hypothyroid women on long-term LT4 therapy and was significantly higher than newly diagnosed hypothyroid and euthyroid individuals (Table 2). BMD was significantly lower in treatment group when compared to other two groups (Table 2). When the patients were divided into three groups based on their duration of treatment, women on treatment for 11–15 years had highest elevation in CTx levels, and it was significantly higher than the other two groups.
As the available data show, some of the work on thyroid hormone’s stimulating effect on bone turnover, mediated via the TSH receptor on osteoblast and osteoclast precursors.9 However, these findings are not supported by some of the studies where bone loss appeared independent of TSH levels in the mice lacking specific TR isoforms.10

In addition to the direct effect, thyroid hormones may also have an indirect effect on bone turnover by involvement of various cytokines and growth factors, including interleukin–6, interleukin-8, prostaglandin E2, insulin-like growth factor-1, matrix metalloproteinase 13, and matrix metalloproteinase 9.20–23

LT4 and BMD. Our study showed reduced BMD in patients on LT4 replacement therapy for more than five years (average of 6.7 years) with minimum dosage of 100 µg/day. Although the BMD values did not cross the cut off for the diagnosis of osteoporosis, they were still in the osteopenic range (as explained by their T-scores). The bone loss was more in patients on treatment for more than 10 years.

Although there is no doubt about decrement in BMD in post-menopausal women, more especially in those on long-term LT4 therapy, it is still debated in premenopausal women.24–26 As the available data show, some of the workers have found significant decrement in BMD,27 while some have failed to find any changes after carefully monitored LT4 therapy.28 Two early cross-sectional studies in premenopausal women demonstrated that LT4 suppressive therapy resulted in lowered BMD of cortical-rich bone.29,30

While most studies support the deteriorating effect of LT4 suppressive therapy on BMD, bone loss because of replacement doses of LT4 has always been debatable. Three prospective trials have demonstrated a reduction in BMD over the treatment period.31–33 The longest trial where patients were followed for one year after the initiation of therapy supports the finding in the current study. Many other studies have shown significant bone loss after a minimum of 7.5 years of LT4 replacement therapy as evidenced by a significant attenuation in speed of sound and stiffness index of the ultrasound measurements at the heel region.34,35

**Table 1.** Baseline characteristics of study group.

| VARIABLES | ON TREATMENT (GROUP I) | NEWLY DIAGNOSED (GROUP II) | EUTHYROID (GROUP III) | P VALUE |
|-----------|------------------------|-----------------------------|-----------------------|---------|
| Age (Years) | 40.25 ± 5.31 | 38.03 ± 5.71 | 37.96 ± 6.34 | 0.252 |
| TSH (µU/ml) | 3.91 ± 2.88 | 11.74 ± 12.47 | 2.42 ± 0.83 | <0.0001 |
| T3 (ng/ml) | 1.19 ± 0.32 | 1.18 ± 0.33 | 1.49 ± 0.51 | 0.01 |
| T4 (µg/dl) | 8.29 ± 2.28 | 7.32 ± 2.06 | 8.70 ± 2.09 | 0.07 |

**Notes:** P value was calculated using ANOVA. P < 0.05 was considered significant.

**Abbreviations:** TSH, Thyroid Stimulating hormone; T3, Triiodothyronine; T4, Thyroxine.

**Table 2.** Distribution of C-terminal telopeptide and BMD in study group.

| VARIABLES | ON TREATMENT (GROUP I) | NEWLY DIAGNOSED (GROUP II) | EUTHYROID (GROUP III) | P VALUE |
|-----------|------------------------|-----------------------------|-----------------------|---------|
| C-terminal telopeptide (ng/ml) | 0.497 ± 0.209 | 0.220 ± 0.079 | 0.244 ± 0.094 | <0.0001 |
| T-score | -2.27 ± 0.48 | -0.17 ± 1.19 | 0.16 ± 1.17 | <0.0001 |
| Z-score | -1.78 ± 0.45 | 0.95 ± 1.25 | 0.95 ± 0.85 | <0.0001 |

**Notes:** P value was calculated using ANOVA. P < 0.05 was considered significant.

**Table 3.** Distribution of variables amongst the patients on levothyroxine therapy based on duration of treatment.

| VARIABLES | 5 YEARS (N = 14) | 6–10 YEARS (N = 9) | 11–15 YEARS (N = 5) | P VALUE |
|-----------|-----------------|-------------------|-------------------|---------|
| C-terminal Telopeptide (ng/ml) | 0.408 ± 0.124 | 0.487 ± 0.216 | 0.827 ± 0.063 | <0.0001 |
| T-score | -1.95 ± 0.37 | -2.42 ± 0.33 | -2.82 ± 0.28 | <0.0001 |
| Z-score | -1.52 ± 0.36 | -1.88 ± 0.33 | -2.22 ± 0.23 | <0.003 |

**Note:** P value <0.05 was considered significant.
measure BMD in these studies was similar to our study as were the findings.

LT4 therapy and CTx. Where there is increased bone turnover, osteoclasts degrade type I collagen and release CTX molecules into the circulation.\textsuperscript{36,37} CTX is being widely proposed to monitor bone loss in post-menopausal osteoporosis and has proven to be a promising diagnostic marker.\textsuperscript{38,39} Significant data are available of its utility in measuring bone resorption in LT4 suppressive therapy. In a randomized controlled trial, Meier et al.\textsuperscript{31} found elevated bone turn over markers DPD (deoxypyridinoline), PYD (pyridinoline), and CTx in the patients taking LT4. No change was observed in patients on placebo. Mikosch et al.\textsuperscript{40} Sijanovic and Karner,\textsuperscript{41} and Schneider et al.\textsuperscript{42} also concluded that CTx is a better bone resorption marker in LT4 suppressive therapy group. Data of its use to detect replacement therapy-induced bone loss are limited.

In this study, CTx was significantly elevated in hypothyroid patients on LT4 therapy, especially in those on treatment for more than 10 years. In addition, there was a significant correlation between dose and duration with CTx levels. It has been noticed that in countries like India, LT4 replacement therapy is poorly monitored mostly because of lack of awareness among a part of patients regarding its possible side effects, and they frequently develop hyperthyroidism on prolonged therapy. Studies have shown elevated bone markers in hyperthyroidism, and hence persistent unmonitored elevated thyroid hormone levels in LT4-treated patients may cause bone loss, which can be detected by bone markers like CTx. CTx also showed significant negative correlation with BMD, more with the T-score and less with the Z-score. Although there are not many studies explaining these correlations in the LT4 replacement therapy group, a study done in premenopausal

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Correlation between C-terminal telopeptide and T-score in patients on levothyroxine treatment.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Correlation between C-terminal telopeptide and Z-score in patients on levothyroxine treatment.}
\end{figure}
women taking LT4 suppressive therapy showed a significant negative correlation between CTx and BMD.\textsuperscript{41}

In this study, CTx did not show any correlation with TSH in total LT4-treated cases, but it showed significant negative correlation in the group with dosage of 150 \( \mu g/\text{day} \) or above (\( r = -0.462, P = 0.047 \)). Our findings are supported by a study done by Heemstra et al.\textsuperscript{43} in which they used CTx as bone turnover marker to evaluate the role of TSH independent of T3 and T4 in bone metabolism and found inversely proportional relationship of CTx with TSH. Although low TSH levels suggest hyperthyroidism and hence with lowering of TSH levels, bone markers should elevate, in this study patients on LT4 therapy maintained TSH levels in euthyroid range (Table 1); hence, no correlation was found in the whole group. On the other hand, when stratified according to dosage, a significant negative correlation was found in those on higher dose of LT4 though the number of subjects was less.

Although it is being proposed as a reliable marker for most of the bone resorption-related disorders, its role has been widely debated because of variations in its levels with age, sex, smoking status, ovulation, concurrent drug use, exercise, circadian rhythms, renal function, and fasting states.\textsuperscript{44} In this study, samples were taken in the morning in fasting states, and hence the possible variability in the results was minimized. Moreover, the patients on calcium supplements, corticosteroids, and antiepileptic drugs were excluded. Patients suffering from kidney diseases were also excluded. All the subjects had regular menstruation cycles, and therefore patients with ovulatory dysfunction were excluded negating the effects of ovulatory dysfunction on CTx.

**Strengths and Limitations**

Adequate sample size, strict patient selection criteria, and careful handling of samples strengthen the reliability of this study. Although information on the etiology of hypothyroidism from majority of the subjects was obtained, the etiology was not correlated with our findings because of unawareness of some of the subjects toward the exact etiology of their disorder. We propose a randomized controlled trial with strict dose regimen of LT4 to further substantiate the present findings.

**Conclusion**

To summarize, LT4 induces bone resorption in hypothyroid individuals especially those on long-term therapy. CTx provides a reliable assessment of the bone status in the above patients and may be used alongside BMD measurement. We conclude that there should be a careful monitoring of LT4 therapy to delay the bone loss by timely monitoring of markers like CTx.

**Author Contributions**

Conceived and designed the experiments: ALC. Analyzed the data: ALC. Wrote the first draft of the manuscript: ALC. Contributed to the writing of the manuscript: PM, RB, VDS. Agree with manuscript results and conclusions: RB, ST, MSR. Jointly developed the structure and arguments for the paper: PM, VDS, ALC, AH. Made critical revisions and approved final version: PM, VDS. All authors reviewed and approved of the final manuscript.

**DISCLOSURES AND ETHICS**

As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.
REFERENCES

1. Joseph L. Radiotopic evaluation of the thyroid and the parathyroids. In: Kronenberg H, Melmed S, Polonsky K, Larsen P. Price D. ed. Williams Text- 
book of Endocrinology. 11th ed. Philadelphia: Saunders, An Imprint of Elsevier; 2008:377–8.

2. Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone prepara-
tions and assessment of current drug use. Thyroid 1994;4(6):605–10.

3. De Rosa G, Testa A, Giacomini D, Carrozza C, Astrai P, Caradonna P. Pros-
pective study of bone loss in pre- and post-menopausal women on L-thyroxine 
therapy for non-toxic goiter. Clin Endocrinol. 1997;47(5):529–35.

4. Lindsay R, Cosman F. Osteoporosis. In: Fauci A, Braunwald E, Kasper D, et al ed. Principles of Internal Medicine. Harcourt. 11th ed. United States of 
America: McGraw-Hill; 2008: 2397–408.

5. Hannan T, Felson T, Dawson-Hughes B. Risk factors for longitudinal bone loss 
in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner 
Res. 2000;15:710–20.

6. Roaige G. Clinical practice. Screening for osteoporosis. N Engl J Med. 
2005;353:164–71.

7. Van de Ven C, Erdtsieck J. Changes of bone mineral density, quantitative ultra-
sound parameters and markers of bone turnover during treatment of hyperthy-
roidism. Ned J Med. 2008;66(10):428–31.

8. Jason A, John S. Thyroid and bone. Endocrine Metab Clin North Am. 
2007;36:673–705.

9. Kricka L. Principles of immunochromatographic techniques. In: Carl B, Edward A, 
David B, eds. Tietz Textbook of Clinical Chemistry. 4th ed. Philadelphia: W.B. Saunder Company; 2006:237.

10. Pagani F, Bonetti G, Stefini F, Pantechnini M. Evaluation of a fully automated 
assay to measure C-telopeptide of type I collagen in serum. Clin Chem Lab Med. 
2000;38(11):1111–3.

11. Gluer C. Quantitative ultrasound techniques for the assessment of osteoporosis. 
Endocrinol Metab Clin North Am. 2007;36:673–705.

12. Roaige G. Clinical practice. Screening for osteoporosis. N Engl J Med. 
2005;353:164–71.

13. Kragstrup J, Melsen F, Mosekilde L. Effects of thyroid hormones on mean wall 
thickness of trabecular bone. Metab Bone Dis Relat Res. 1981;3:181–6.

14. Mosekilde L, Melsen F. Morphometric and dynamic studies of bone changes in 
patients with thyroid function disorders. J Clin Endocrinol Metab. 1986;64:48.

15. Mundy GR, Shapiro JL, Bandelin JG. Direct stimulation of bone resorption by 
thyroid hormone receptors in human bone. Acta Pathol Microb Scand A. 
1994;134:169–76.

16. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate 
thyroid hormone effects on bone growth and function. Mol Genet Metab. 2002;75:17.

17. Abu EO, Bord S, Horner A. The expression of thyroid hormone receptors in 
human bone. Bone. 1990;72:1184–8.

18. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate 
thyroid hormone effects on bone growth and function. Mol Genet Metab. 2002;75:17.

19. Franklyn J, Betteridge J, Holder R. Bone mineral density in thyroxine treated 
females with or without a previous history of thyrotoxicosis. Clin Endocrinol. 
1994;41:425–32.

20. Gardner M, Reid I, Loveridge, N. Bone mineral density and metabolism in pre-
menopausal women taking L-thyroxine replacement therapy. Clin Endocrinol. 
2007;65(12):2397–410.

21. Lehmk J, Bogner U, Felsenberg D, Peters H, Schleusener H. Determination of 
bone mineral density by quantitative computed tomography and single photon 
absorptionmetry in subclinical hyperthyroidism: a risk of early osteopenia in post-
menopausal women. J Clin Endocrinol Metab. 1992;36:511–7.

22. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk 
factors, prediction of risk using serum CTX testing, prevention, and treatment. 
J Oral Maxillofac Surg. 2010;68(9):2241–7.

23. Schneider R, Schneider M, Reiners C, Schneider P. Effects of levothyroxine on 
markers of bone turnover in patients with subclinical hyperthyroidism. A randomized controlled trial. Osteoporos Int. 
2004;15(3):209–16.

24. Ribot C, Tremolieres F, Poulies J, Louver JP. Bone mineral density and thyroid 
hormone therapy. Clin Endocrinol (Oxf). 1990;33:143.

25. Nuttall F, Horan S, Aronson D, Stuenkel C, Fulmer JP. Thyroid hormone 
and postmenopausal thyroid carcinoma. J Clin Endocrinol Metab. 2008;93(5):164–71.

26. Coindre J, David J, Riviere L, et al. Bone loss in hypothyroidism with hormone 
replacement: a histomorphometric study. Arch Intern Med. 1985;145:48.

27. Kung A, P. Bone mineral density in premenopausal women receiving long-
term physiological doses of levothyroxine. JAMA. 1991;265:2688.

28. Hadji P, Hars O, Strum G, Bauer T, Emons G, Schulz KD. The effect of long-
term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of 
bone in women. Eur J Endocrinol. 2000;142:445.

29. Pasch M. Bone mineral density in postmenopausal women with or without a 
previous history of thyrotoxicosis. Eur J Endocrinol. 2007;156:517–24.

30. Kragstrup J, Melsen F, Mortensen J, et al. Long-term, non-suppressive levothyroxine treatment and bone loss in patients with sub-
clinical hyperthyroidism: a randomized controlled trial. Osteoporos Int. 
2004;15(3):209–16.

31. Meier C, Bear M, Guglielmetti M, Christ-Crain M, Staub JJ, Kraenzlin M. 
Restoration of euthyroidism accelerates bone turnover in patients with sub-
clinical hyperthyroidism: a randomized controlled trial. J Bone Miner Res. 
2004;19:344–51.

32. Pasch M. C-terminal cross-linking telopeptide as a serologic marker for bispho-
 sphate-related osteonecrosis of the jaw: review of 2 cases. J Can Dent Assoc. 
2013;79:d51.